1C.-D. Schiller,M. R. Schneider,H. Hartmann,A.-H. Graf,H. Klocker,G. Bartsch.Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma[J]. Urological Research . 1991 (1)
2Scher HI,Heller G.Clinical states in prostate cancer:toward a dynamic model of disease progression. Urology . 2000
3Montgomery RB,Mostaghel EA,Vessella R,et al.Maintenance of intratumoral androgens in metastatic prostate cancer:a mechanism for castration-resistant tumor growth. Cancer Research . 2008
4Labrie F.Adrenal androgens and intracrinology. Seminars in Reproductive Medicine . 2004
5Klein H,Bressel M,Kastendieck H,et al.Androgens,adrenal androgen precursors,and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer. American Journal of Clinical Oncology . 1988
6Montgomery B,Mostaghel E,Vessella R,et al.Androgen synthesis in castration-adapted metastatic prostate cancer. Journal of Clinical Oncology . 2007
7Tindall D,Horne FM,Hruszkewycz A,et al.Symposium on androgen action in prostate cancer. Cancer Research . 2004
8Attard G,Reid AH,Yap TA,et al.PhaseⅠclinical trial of a selective inhibitor of CYP17,abiraterone acetate,confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology . 2008
9D.C. Danila,M.J. Morris,J.S. Bono.Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel. Journal of Clinical Oncology . 2010
10Auchus,RJ.The backdoor pathway to dihydrotestosterone. Trends in Endocrinology and Metabolism . 2004
